rss
Ann Rheum Dis doi:10.1136/ard.2008.093757

A randomised controlled trial of spinal manipulative therapy in acute low back pain

  1. Peter Jüni (juni{at}ispm.unibe.ch)
  1. University of Bern, Switzerland
    1. Markus Battaglia (battag{at}ispm.unibe.ch)
    1. Medix General Practice Network, Switzerland
      1. Eveline Nüesch (enueesch{at}ispm.unibe.ch)
      1. University of Bern, Switzerland
        1. Gerard Hämmerle (gerard.haemmerle{at}kws.ch)
        1. Schulthess Clinic Zürich, Switzerland
          1. Prisca Eser (peser{at}ispm.unibe.ch)
          1. University of Bern, Switzerland
            1. Roger van Beers (roger.vanbeers{at}praxis-bubenberg.ch)
            1. Medix General Practice Network, Switzerland
              1. Daniel Vils (daniel.vils{at}praxis-bubenberg.ch)
              1. Medix General Practice Network, Switzerland
                1. Jürg Bernhard (jbernhard_so{at}spital.ktso.ch)
                1. Kantonspital Solothurn, Switzerland
                  1. Hansruedi Ziswiler (hansruedi.ziswiler{at}insel.ch)
                  1. Inselspital Bern, Switzerland
                    1. Madeleine Dähler (daehler{at}ispm.unibe.ch)
                    1. University of Bern, Switzerland
                      1. Stephan Reichenbach (rbach{at}ispm.unibe.ch)
                      1. University of Bern, Switzerland
                        1. Peter M Villiger (peter.villiger{at}insel.ch)
                        1. Inselspital Bern, Switzerland
                          • Published Online First 5 September 2008

                          Abstract

                          Objective: To determine whether treatment with spinal manipulative therapy (SMT) administered in addition to standard care is associated with clinically relevant early reductions in pain and analgesic consumption.

                          Methods: We randomised 104 patients with acute low back pain to SMT in addition to standard care (n=52) or standard care alone (n=52). Standard care consisted of general advice and paracetamol, diclofenac or dihydrocodein as required. Other analgesic drugs or non-pharmacological treatments were not allowed. Primary outcomes were pain intensity assessed on the 11 point box scale (BS-11) and analgesic use based on diclofenac equivalence doses during days 1 to 14. An extended follow-up was performed at 6 months.

                          Results: Pain reductions were similar in experimental and control groups, with the lower limit of the 95% confidence interval (95%-CI) excluding a relevant benefit of SMT (difference 0.5 on the BS-11, 95%-CI -0.2 to 1.2, p=0.13). Analgesic consumptions were also similar (difference -18 mg diclofenac equivalents, 95%-CI -43 mg to 7 mg, p=0.17), with small initial differences diminishing over time. There were no differences between groups in any of the secondary outcomes and stratified analyses provided no evidence for potential benefits of SMT in specific patient groups. The extended follow-up showed similar patterns.

                          Conclusions: SMT is unlikely to result in relevant early pain reduction in patients with acute low back pain. [clinicaltrials.gov Identifier: NCT00294229]

                          Register for free content


                          Free sample
                          This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of ARD.
                          View free sample issue >>

                          Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

                        1. Latest Rheumatology Jobs

                          Rheumatology Jobs